TD Cowen analyst Joshua Jennings initiated coverage of Anteris Technologies (AVR) with a Buy rating and $15 price target Anteris has developed DurAVR, a first-in-class biomimetic transcatheter aortic valve replacement platform that has “disruptive potential,” the analyst tells investors in a research note. The firm says the hemodynamic outcomes generated in the clinical development program are differentiated and could drive Anteris to capture meaningful share in the $10B TAVR market in replicated in the next trial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue